<DOC>
	<DOC>NCT01165268</DOC>
	<brief_summary>It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.</brief_summary>
	<brief_title>Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria for T2DM Diagnosis of T2DM Must be on one of the following therapies: diet therapy alone, diet plus a sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin Subjects taking metformin, and/or sulfonylurea must be on a stable dose for at least 2 months prior to study drug administration Must have a fasting plasma glucose concentration ≤ 200 mg/dl, and HbA1C ≤ 10% Inclusion criteria for healthy subjects: Healthy subjects (as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations) Inclusion criteria for all subjects: Subjects with (eGFR ≥ 60 and ≤ 160 mL/min/1.73m² and urinary albumin excretion &lt; 300 mg/g creatinine) Body Mass Index (BMI) of 18 to 38 kg/m² Men and women, ages 18 to 65 years, inclusive Exclusion criteria for all subjects: Subjects with Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus Subjects with T2DM with fasting plasma glucose &gt; 200 mg/dL, healthy subjects with fasting plasma glucose &gt; 105 mg/dL Subjects with T2DM with HbA1C &gt; 10.0%, healthy subjects with HbA1C &gt; 6.8%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>